Cargando…
Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
BACKGROUND: Historical restrictions on take-home medications for opioid use disorder have generated considerable debate. The COVID-19 pandemic shifted the perceived risks and benefits of daily clinic attendance and led to widespread policy reform, creating an unprecedented opportunity to explore the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165059/ https://www.ncbi.nlm.nih.gov/pubmed/37182352 http://dx.doi.org/10.1016/j.drugpo.2023.104058 |
_version_ | 1785038187141267456 |
---|---|
author | Adams, Alison Blawatt, Sarin MacDonald, Scott Finnick, Rhys Lajeunesse, Julie Harrison, Scott Byres, David Schechter, Martin T. Oviedo-Joekes, Eugenia |
author_facet | Adams, Alison Blawatt, Sarin MacDonald, Scott Finnick, Rhys Lajeunesse, Julie Harrison, Scott Byres, David Schechter, Martin T. Oviedo-Joekes, Eugenia |
author_sort | Adams, Alison |
collection | PubMed |
description | BACKGROUND: Historical restrictions on take-home medications for opioid use disorder have generated considerable debate. The COVID-19 pandemic shifted the perceived risks and benefits of daily clinic attendance and led to widespread policy reform, creating an unprecedented opportunity to explore the impact of more flexible prescribing. We conducted a qualitative systematic review to synthesize the evidence on providers’ experiences with relaxing restrictions on take-home doses of medications prescribed for opioid use disorder during the COVID-19 pandemic. METHODS: The protocol for this systematic review was registered in PROSPERO (CRD42022360589; https://www.crd.york.ac.uk/prospero/). From Sept.–Nov. 2022, we searched Medline, Embase, CINAHL, PsycInfo, Web of Science, the Cochrane Register of Controlled Trials, and the grey literature from 2020 onward. Studies were eligible for inclusion if they used qualitative methods to investigate providers’ experiences with relaxed restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic. We appraised study quality using the CASP qualitative checklist and used thematic synthesis and GRADE-CERQual to synthesize the results. RESULTS: We retrieved 13 articles representing 11 studies. Six were conducted in the United States and most focused on changes to methadone treatment. Providers’ experiences with increased flexibilities around take-homes were broadly positive, despite widespread initial concern over client safety and the potential for medication misuse. For a small number of providers, concerns about diversion were a specific manifestation of more general unease with loss of control over clients and the treatment process. Most providers appreciated increased flexibilities and described them as enabling more individualized, person-centered care. CONCLUSION: Our findings support the continuation of flexibilities around take-homes and demonstrate that regulations and policies that reduce flexibility around take-homes conflict with person-centered approaches to care. Stronger guidance and support from professional regulatory agencies may help increase uptake of flexibilities around take-homes. |
format | Online Article Text |
id | pubmed-10165059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101650592023-05-08 Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review Adams, Alison Blawatt, Sarin MacDonald, Scott Finnick, Rhys Lajeunesse, Julie Harrison, Scott Byres, David Schechter, Martin T. Oviedo-Joekes, Eugenia Int J Drug Policy Review BACKGROUND: Historical restrictions on take-home medications for opioid use disorder have generated considerable debate. The COVID-19 pandemic shifted the perceived risks and benefits of daily clinic attendance and led to widespread policy reform, creating an unprecedented opportunity to explore the impact of more flexible prescribing. We conducted a qualitative systematic review to synthesize the evidence on providers’ experiences with relaxing restrictions on take-home doses of medications prescribed for opioid use disorder during the COVID-19 pandemic. METHODS: The protocol for this systematic review was registered in PROSPERO (CRD42022360589; https://www.crd.york.ac.uk/prospero/). From Sept.–Nov. 2022, we searched Medline, Embase, CINAHL, PsycInfo, Web of Science, the Cochrane Register of Controlled Trials, and the grey literature from 2020 onward. Studies were eligible for inclusion if they used qualitative methods to investigate providers’ experiences with relaxed restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic. We appraised study quality using the CASP qualitative checklist and used thematic synthesis and GRADE-CERQual to synthesize the results. RESULTS: We retrieved 13 articles representing 11 studies. Six were conducted in the United States and most focused on changes to methadone treatment. Providers’ experiences with increased flexibilities around take-homes were broadly positive, despite widespread initial concern over client safety and the potential for medication misuse. For a small number of providers, concerns about diversion were a specific manifestation of more general unease with loss of control over clients and the treatment process. Most providers appreciated increased flexibilities and described them as enabling more individualized, person-centered care. CONCLUSION: Our findings support the continuation of flexibilities around take-homes and demonstrate that regulations and policies that reduce flexibility around take-homes conflict with person-centered approaches to care. Stronger guidance and support from professional regulatory agencies may help increase uptake of flexibilities around take-homes. Elsevier B.V. 2023-07 2023-05-08 /pmc/articles/PMC10165059/ /pubmed/37182352 http://dx.doi.org/10.1016/j.drugpo.2023.104058 Text en © 2023 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Adams, Alison Blawatt, Sarin MacDonald, Scott Finnick, Rhys Lajeunesse, Julie Harrison, Scott Byres, David Schechter, Martin T. Oviedo-Joekes, Eugenia Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review |
title | Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review |
title_full | Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review |
title_fullStr | Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review |
title_full_unstemmed | Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review |
title_short | Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review |
title_sort | provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the covid-19 pandemic: a qualitative systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165059/ https://www.ncbi.nlm.nih.gov/pubmed/37182352 http://dx.doi.org/10.1016/j.drugpo.2023.104058 |
work_keys_str_mv | AT adamsalison providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview AT blawattsarin providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview AT macdonaldscott providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview AT finnickrhys providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview AT lajeunessejulie providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview AT harrisonscott providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview AT byresdavid providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview AT schechtermartint providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview AT oviedojoekeseugenia providerexperienceswithrelaxingrestrictionsontakehomemedicationsforopioidusedisorderduringthecovid19pandemicaqualitativesystematicreview |